---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059527"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:20:05.008813+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics Q1 net loss $16.6M; Phase 2 TR-MAC data expected August 2024

## Summary
- Net loss of $16.6M for Q1 2024 vs $15.3M in Q1 2023; cash $118.1M.
- R&D spend $14.7M, up from $12.0M YoY; G&A $3.6M, down from $4.1M.
- Phase 3 enrollment paused Feb 2024 due to blinded aggregate efficacy signal; no safety issues.
- 97 patients remain in Phase 3; topline Phase 2 data from EBO-301 due August 2024.
- Epetraborole targets treatment-refractory MAC lung disease with high unmet need.

## SEC filing metadata
- accession: 0000950170-24-059527
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000095017024059527/0000950170-24-059527-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000095017024059527/antx-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059527
- JSON: https://secwatch.observer/filing/0000950170-24-059527.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059527.txt

## Key facts
- Earnings Releases
  AN2 Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $16.6 million.
  - Period: the quarter ended March 31, 2024
  - Net income: Net loss for the first quarter of 2024 was $16.6 million
  - Result: reported results
  source text: AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1880438/000095017024059527/0000950170-24-059527-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.